Research
Hormonal
Pharmacological inhibition of the mTOR pathway using rapamycin extends lifespan in mice and is currently being tested in humans, though it carries metabolic side effects like insulin resistance.
Rapamycin extends mouse lifespan significantly but has side effects like insulin resistance. Human trials are currently underway to determine safe dosing for healthy older adults. Do not self-administer; wait for clinical trial results.
GoodQualifiesMEDIUM confidence
Rapamycin... has been shown to extend lifespan in mice, up to 30% in females at high doses... The adverse effects of rapamycin include metabolic dysregulation (e.g., hyperglycemia, hyperinsulinemia, and insulin resistance)... Currently, several trials testing rapamycin are ongoing in healthy older populations.
Why this rating
Strong evidence in mice (30% lifespan extension); human trials are ongoing, so human efficacy/safety is not yet fully established.
Source
Interventions to Slow Aging in Humans: Are We Ready?
Valter D. Longo et al. · Aging Cell · 2015
DOI 10.1111/acel.12338
narrative_reviewCited 596×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Intermittent fasting (IF) and prolonged fasting (PF) are safe and effective interventions that mimic the health benefits of chronic dietary restriction, including reduced inflammation and improved insulin sensitivity, without the severe side effects of continuous caloric restriction.Moderate
- Pharmacological inhibition of the GH/IGF-1 axis, specifically using the GH receptor antagonist pegvisomant, lowers IGF-1 levels and improves insulin sensitivity, making it a candidate for extending healthspan.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →